Compare PAX & ANIP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | PAX | ANIP |
|---|---|---|
| Founded | 1988 | 2001 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.8B | 1.9B |
| IPO Year | 2020 | 1999 |
| Metric | PAX | ANIP |
|---|---|---|
| Price | $9.54 | $74.52 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 6 | 9 |
| Target Price | $14.83 | ★ $105.78 |
| AVG Volume (30 Days) | ★ 1.5M | 314.1K |
| Earning Date | 11-03-2026 | 11-05-2026 |
| Dividend Yield | ★ 6.66% | N/A |
| EPS Growth | N/A | ★ 419.23 |
| EPS | N/A | ★ 3.86 |
| Revenue | N/A | ★ $206,547,000.00 |
| Revenue This Year | $13.22 | $24.85 |
| Revenue Next Year | $9.41 | $10.76 |
| P/E Ratio | $25.65 | ★ $18.56 |
| Revenue Growth | N/A | ★ 2.47 |
| 52 Week Low | $9.03 | $69.58 |
| 52 Week High | $17.80 | $95.45 |
| Indicator | PAX | ANIP |
|---|---|---|
| Relative Strength Index (RSI) | 38.96 | 46.82 |
| Support Level | N/A | $69.93 |
| Resistance Level | $11.74 | $74.29 |
| Average True Range (ATR) | 0.40 | 1.83 |
| MACD | -0.21 | 0.00 |
| Stochastic Oscillator | 23.40 | 38.27 |
Patria Investments Ltd is an alternative asset management firm specializing in resilient sectors across select regions. It seeks to provide world-wide and Latin American investors with attractive investment products that allows portfolio diversification and consistent returns. The group promotes inclusive and sustainable development in the Asset Classes: Private Equity, Private Equity Solutions, Credit, Real Estate, Infrastructure, and Public Equities Main sectors: Agribusiness, Power & Energy, Healthcare, Logistics & Transportations, Food & Beverage and Digital & Tech Services Investment Regions.
ANI Pharmaceuticals Inc is a diversified biopharmaceutical company. It is focused on developing, manufacturing, and commercializing therapeutics through its Rare Disease business, which markets novel products in the areas of ophthalmology, rheumatology, nephrology, neurology, and pulmonology; and through its Generics and Brands businesses. The firm's product portfolio comprises Purified Cortrophin Gel, ILUVIEN, and YUTIQ (fluocinolone acetonide intravitreal implant), among others. Additionally, its Generics portfolio includes several products with a wide variety of indications. The company has two operating segments: Rare Disease and Brands, which derive maximum revenue, and Generics and Other. Geographically, it generates maximum revenue from the United States, followed by other markets.